Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 15/20 | 0.41 |
| ▸ | MAG | P20916 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24630057 | 0.90 | CD22 (0.39) | CD22MAGLMNA | |
| SCHEMBL29326282 | 0.90 | CD22 (0.42) | CD22MAG | |
| SCHEMBL29326548 | 0.90 | CD22 (0.38) | CD22MAGLMNA | |
| SCHEMBL31225924 | 0.89 | CD22 (0.39) | CD22MAG | |
| SCHEMBL29326558 | 0.88 | CD22 (0.38) | CD22MAGLMNA | |
| SCHEMBL29326540 | 0.88 | CD22 (0.37) | CD22MAGLMNA | |
| SCHEMBL29727791 | 0.87 | CD22 (0.39) | CD22MAGLMNA | |
| SCHEMBL27391586 | 0.87 | CD22 (0.39) | CD22MAGLMNA | |
| SCHEMBL31225919 | 0.85 | CD22 (0.41) | CD22MAG | |
| SCHEMBL24629735 | 0.85 | CD22 (0.36) | CD22MAGLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| EP-4274582-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | Osprey Biopharmaceuticals, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150726-A1 | HYPOIMMUNOGENIC BIOTHERAPEUTICS | OSPREY BIOPHARMACEUTICALS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CD22 18/4885MAG 321/4885LMNA 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.